Ataibeckley INC

AtaiBeckley Inc. has been acquired by Eli Lilly and Company, with shareholders receiving $6.75 in cash and a contingent value right per share.

AtaiBeckley Inc. announced the overwhelming approval of its merger with Eli Lilly and Company by its shareholders, paving the way for a September 11, 2026, closing.

AtaiBeckley Inc. reports that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its merger with Eli Lilly and Company has expired, signaling continued progress towards the transaction's completion.

Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley Inc. for $6.75 per share in cash plus a contingent value right (CVR) for potential future payments.

AtaiBeckley Inc. has entered into a merger agreement with Eli Lilly and Company for an acquisition valued at $6.75 per share plus contingent value rights, while reporting Q2 2026 results with increased R&D expenses and continued net losses.

Gerd Kochendoerfer, Chief Operating Officer of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

Kevin James Craig, Chief Medical Officer of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

Anne Nagengast Johnson, Chief Accounting Officer of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

Christopher Ryan Cave Barrett, See remarks of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

Glenn Frank Short, Chief Scientific Officer of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

Michael E. Faerm, Chief Financial Officer of AtaiBeckley Inc., reported multiple transactions in common stock on September 11, 2026.

AtaiBeckley Inc. confirms the consummation of its merger with Eli Lilly and Company, resulting in reporting persons Apeiron Investment Group Ltd. and others ceasing to beneficially own any shares.

AtaiBeckley Inc. announces a merger agreement with Eli Lilly and Company, with key shareholders Apeiron Investment Group Ltd. and Christian Angermayer entering into voting and support agreements.